Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection - Concepedia

Concepedia

Publication | Open Access

Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection

DOI Full Paper Access

134

Citations

14

References

2014

Year

Andre S. Nell, Eva D’lom, Patrick Bouic, M. Sabaté, R. Bosser, Jordi Picas, Mercè Amat, Gavin Churchyard, Père-Joan Cardona

Abstract

ClinicalTrials.gov NCT01136161.

References

	Year	Citations

Page 1